Ser119

Site Information
GEEEHVysFPNkQks SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 465475
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:	breast cancer ( 1 , 8 , 13 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 ) , esophageal cancer, surrounding tissue ( 18 ) , gastric cancer ( 12 ) , gastric carcinoma ( 12 ) , leukemia ( 15 ) , chronic lymphocytic leukemia ( 15 ) , liver cancer ( 19 ) , lung cancer ( 5 , 8 , 9 , 10 , 16 , 17 , 23 ) , non-small cell lung cancer ( 5 , 6 , 7 , 8 , 9 , 10 , 16 , 17 , 23 ) , non-small cell lung adenocarcinoma ( 5 , 16 , 17 ) , non-small cell large cell lung carcinoma ( 5 ) , non-small cell squamous cell lung carcinoma ( 7 ) , neuroblastoma ( 3 ) , melanoma skin cancer ( 20 ) , thyroid cancer ( 21 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) ( 16 ) , breast ( 2 , 13 ) , BT-549 (breast cell) ( 8 ) , E.coli (bacterial) ( 1 ) , esophagus ( 18 ) , H2009 (pulmonary) ( 8 ) , H2077 (pulmonary) ( 8 ) , H2887 (pulmonary) ( 8 ) , H322M (pulmonary) ( 8 ) , HCC1359 (pulmonary) ( 8 ) , HCC2279 (pulmonary) ( 8 ) , HCC4006 (pulmonary) ( 8 ) , HEK293T (epithelial) ( 1 ) , HeLa (cervical) ( 1 , 4 , 22 ) , HOP62 (pulmonary) ( 8 ) , liver ( 19 ) , lung ( 5 ) , MDA-MB-231 (breast cell) ( 1 , 8 ) , MKN-45 (gastric) ( 12 ) , NCI-H1299 (pulmonary) ( 5 ) , NCI-H1568 (pulmonary) ( 8 ) , NCI-H157 (pulmonary) ( 8 ) , NCI-H1650 (pulmonary) ( 9 , 10 , 17 ) , NCI-H1666 (pulmonary) ( 8 ) , NCI-H1703 (squamous) ( 7 ) , NCI-H1734 (pulmonary) ( 5 ) , NCI-H1944 (pulmonary) ( 5 ) , NCI-H2172 (pulmonary) ( 8 ) , NCI-H322 (pulmonary) ( 8 ) , NCI-H3255 (pulmonary) ( 6 , 23 ) , NCI-H358 (pulmonary) ( 5 ) , NCI-H460 (pulmonary) ( 5 ) , NCI-H520 (squamous) ( 8 ) , NCI-H647 (pulmonary) ( 8 ) , PC9 (pulmonary) ( 8 ) , SH-SY5Y (neural crest) ( 3 ) , skin ( 20 ) , thyroid ( 21 )

Upstream Regulation
Putative in vivo kinases:	ULK1 (human) ( 1 ) , ULK2 (human) ( 1 )
Kinases, in vitro:	ULK1 (human) ( 1 ) , ULK2 (human) ( 1 )
Treatments:	(-)-Blebbistatin ( 1 ) , Rho activator II ( 1 ) , SBI-0206965 ( 1 ) , siRNA ( 1 ) , stiff ECM substrate ( 1 )

Downstream Regulation
Effects of modification on PXN:	molecular association, regulation ( 1 )
Effects of modification on biological processes:	carcinogenesis, inhibited ( 1 ) , cell motility, inhibited ( 1 ) , cytoskeletal reorganization ( 1 )
Inhibit interaction with:	FAK (human) ( 1 ) , GIT1 (human) ( 1 ) , Hic-5 (human) ( 1 ) , Src (human) ( 1 ) , kindlin-2 (human) ( 1 )

References
1	Liang P, et al. (2023) An ULK1/2-PXN mechanotransduction pathway suppresses breast cancer cell migration. EMBO Rep, e56850 37846507 Curated Info
2	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
3	Palacios-Moreno J, et al. (2015) Neuroblastoma Tyrosine Kinase Signaling Networks Involve FYN and LYN in Endosomes and Lipid Rafts. PLoS Comput Biol 11, e1004130 25884760 Curated Info
4	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
5	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
6	Rikova K (2012) CST Curation Set: 16138; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954 Curated Info
7	Rikova K (2012) CST Curation Set: 16139; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954 Curated Info
8	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
9	Possemato A (2012) CST Curation Set: 14062; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
10	Possemato A (2012) CST Curation Set: 14063; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
11	Rikova K (2012) CST Curation Set: 13731; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 3/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876 Curated Info
12	Mulhern D (2012) CST Curation Set: 13405; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
13	Tucker M (2011) CST Curation Set: 10931; Year: 2011; Biosample/Treatment: tissue, breast/untreated; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
14	Rikova K (2010) CST Curation Set: 10044; Year: 2010; Biosample/Treatment: cell line, DFCI ERC17 triple/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
15	Rikova K (2010) CST Curation Set: 10034; Year: 2010; Biosample/Treatment: cell line, DFCI ERC11/untreated; Disease: chronic lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
16	Moritz A (2009) CST Curation Set: 7288; Year: 2009; Biosample/Treatment: cell line, A549/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
17	Moritz A (2009) CST Curation Set: 7284; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
18	Gu T (2009) CST Curation Set: 7008; Year: 2009; Biosample/Treatment: tissue, esophagus/untreated; Disease: esophageal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
19	Gu T (2009) CST Curation Set: 6572; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
20	Tucker M (2009) CST Curation Set: 6435; Year: 2009; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
21	Gu T (2008) CST Curation Set: 4955; Year: 2008; Biosample/Treatment: tissue, thyroid/untreated; Disease: thyroid cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
22	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
23	Moritz A (2007) CST Curation Set: 2777; Year: 2007; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info